On May 16, 2018 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, reported that an abstract highlighting X4P-001-IO, the company’s CXCR4 antagonist, has been selected for poster presentation at the 2018 Association Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, taking place June 1-5 in Chicago (Press release, X4 Pharmaceuticals, MAY 16, 2018, View Source [SID1234526725]). The presentation will describe clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation on X4P-001 are as follows:
Title: A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma
Authors:
Ulka Vaishampayan, M.D., Barbara Ann Karmanos Cancer Institute, Detroit, MI
Michael Atkins, M.D., Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC
Abstract #: 4510
Poster Session: Genitourinary (Nonprostate) Cancer
Session Type:
Poster Discussion Session, chosen as a select poster where expert discussants will highlight the most clinically applicable and novel posters, with abstract authors participating as panel members
Date and Time: June 2, 2018, 1:15 PM-2:30 p.m. CT
About X4P-001-IO in Cancer
X4P-001-IO is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.